Biopharmaceutical company
RNA interference scientific advancements; ensuring patient access to the Medicare home infusion benefit for drugs newly approved by the FDA after the establishment of the home infusion benefit; differentiation of genetically-targeted therapies, H.R.5376 - Build Back Better Act Clarification and transparency with respect to Section 529A of the Food, Drug and Cosmetic Act for genetically-targeted technologies
MMM - Medicare/Medicaid MED - Medical/Disease Research/Clinical Labs
1 - SENATE 1 - SENATE
SPLITOAK STRATEGIES LLC
300 New Jersey Avenue, NW, Suite 900, Washington, DC, 20001, US
SARAH KUEHL EGGE (1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction) SARAH KUEHL EGGE (1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction)
1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Senate Budget Committee (Senator Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee on Deficit Reduction 1998-2000 Legislative Assistant to Senator Bob Kerrey; 2001-2012 Senior Budget Analyst for Democratic Staff of the Senate Budget Committee (Kent Conrad); Fall 2011, Deputy Staff Director, Joint Select Committee for Deficit Reduction